Clearmind Medicine CMND 深 滬
已收盤 10-17 16:00:00 美东时间
0.9578
+0.011
+1.11%
華盛通- 最 高0.9667
- 今 開0.9337
- 成交量 12.90万股
- 最 低 0.9307
- 昨 收 0.9473
- 總市值 515.24万
- 52周最高 2.18
- 市盈率 靜 --
- 換手率 2.40%
- 52周最低 0.80
- 委 比 -84.86%
- 總股本 537.94万
- 歷史最高 183.00
- 量 比 2.22
- 振 幅 3.80%
- 歷史最低 0.80
- 每 手 1
- 風險率 0.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Clearmind Medicine Inc. announce the successful inaugural meeting of its Scientific Advisory Board, focusing on MEAI, their lead candidate for AUD, with potential applications in obesity and mental health. The company highlighted promising safety data and strategic opportunities, supported by a strong IP portfolio of 31 granted patents.
09-25 11:40
Clearmind Medicine Enters $10M Convertible Note Agreement With Institutional Investors, Begins With $555K Issuance At $500K Purchase Price
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
09-19 20:21
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Clearmind Medicine Inc., a psychedelic-derived therapeutics company, has entered into securities purchase agreements with institutional investors, enabling them to issue up to $10 million in convertible promissory notes. The Company issued initial notes worth $555,556 for $500,000 and plans to use proceeds for working capital, general corporate purposes, and potential acquisitions to explore strategic opportunities. Aegis Capital Corp. acted as f...
09-19 12:20
Clearmind Medicine Publishes International Patent Application For Therapy Targeting Obesity And Metabolic Syndrome In Collaboration With SciSparc
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
08-07 19:39
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Clearmind Medicine Inc. and SciSparc Ltd. announced a joint international patent application under the PCT for a novel combination therapy targeting metabolic syndrome and obesity. This therapy combines Clearmind's MEAI and SciSparc's PEA, leveraging their complementary pharmacological properties. The collaboration, which has resulted in 13 patent families across multiple jurisdictions, aims to develop innovative treatments for mental health diso...
08-07 11:32
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. and Clearmind Medicine Inc. have filed a new international patent application for their innovative combination therapy targeting obesity and MASLD. The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA), leveraging its unique pharmacological properties. The collaboration aims to address significant global health challenges, with obesity affecting over 890 million people and NAFLD...
07-30 12:12
Clearmind Medicine Completes Site Initiation At Tel Aviv Sourasky Medical Center For Phase I/IIa Clinical Trial Evaluating CMND-100, Proprietary Oral Drug Candidate For AUD
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major
07-23 20:56
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Clearmind Medicine Inc. expands its Phase I/IIa trial for CMND-100, an oral treatment for Alcohol Use Disorder, by adding a site at Johns Hopkins University and enrolling its first participant there. The trial evaluates safety, tolerability, and pharmacokinetics, while assessing potential reductions in alcohol cravings and consumption. This follows the recent enrollment of the first participant at Yale School of Medicine, strengthening Clearmind’...
07-15 12:05
Clearmind Medicine Granted U.S. Patent #12,350,242 For "BINGE BEHAVIOR REGULATORS"
https://ppubs.uspto.gov/api/pdf/downloadPdf/12350242?requestToken=eyJzdWIiOiJlMmEyMTIwZi01YWZmLTQ5NGMtYjFkYi1lZTVmMmQ3MzM4NDgiLCJ2ZXIiOiJkNTc5MmM2MC00MzhmLTRkOGItODRjNy1iZWM5NjU2YjRjZTQiLCJleHAiOjB9
07-09 04:00
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Clearmind Medicine Inc. received IRB approval from Tel Aviv Sourasky Medical Center for its Phase 1/2a clinical trial of CMND-100, a psychedelic-derived drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at leading institutions including Yale, Johns Hopkins, and Hadassah-University Medical Center, aims to assess CMND-100's safety, tolerability, and efficacy in reducing alcohol cravings. The approval marks a significant s...
07-03 12:47
